Belite Bio, Inc
NASDAQ:BLTEBiotechnology
Healthcare
$156.23 +0.31%
+$0.46 today
- Market cap
- $6.29B
- Beta
- -1.24
- P/E (TTM)
- -65.9
- EPS (TTM)
- -$2.26
52W Low $56.10High $200.00
Volume 0.09M
Average 0.17M
BLTE Pre-Tax Margin
Income before tax as a percentage of revenue.
No reported Pre-Tax Margin figures are available to summarize.
Pre-Tax Margin history
Percent of revenue · from the income statement
No Pre-Tax Margin data reported for this period type.
Pre-Tax Margin vs competitors
How BLTE compares with its peers on the latest reported figures
BLTE Competitors Peer median
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
IRDOpus Genetics, Inc. | LTM Mar 2026 | -892.4% | -462.9 pp | -395.0 pp |
| LTM Mar 2026 | -1605.2% | -334.1 pp | +1951.5 pp | |
| LTM Mar 2026 | -3563.6% | -3301.9 pp | -491.6 pp | |
BLTEBelite Bio, Inc | FY2025 | — | — | — |
| FY2025 | — | — | — | |
KLRSKalaris Therapeutics Inc | FY2025 | — | — | — |
| Peer median (excluding BLTE) | -1605.2% | -462.9 pp | -395.0 pp | |
Competitors are the stored peer set for BLTE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 7.42M | 8.87M | 24.84M | 29.94M | 45.38M |
| Selling, General & Admin | 2.38M | 3.95M | 6.82M | 10.06M | 38.83M |
| Operating Expenses | 9.8M | 12.82M | 31.67M | 40M | 84.21M |
| Depreciation & Amortization | 30K | 198K | 399K | 449K | 464K |
| EBITDA | (9.64M) | (12.43M) | (31.2M) | (35.67M) | (77.15M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (9.8M) | (12.82M) | (31.67M) | (40M) | (84.21M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 5K | 23K | 74K | 3.74M | 0 |
| Interest Expense | 0 | 16K | 25K | 20K | 0 |
| Other Income / Expenses | 131K | 173K | 45K | 3.86M | 6.6M |
| Income Before Tax | (9.67M) | (12.65M) | (31.62M) | (36.14M) | (77.61M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 9K | 6K | 0 |
| Net Income | (9.67M) | (12.65M) | (31.63M) | (36.14M) | (77.61M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.40) | (0.63) | (1.19) | (1.18) | (2.31) |
| EPS (Diluted) | (0.40) | (0.63) | (1.19) | (1.18) | (2.31) |
| Weighted Avg Shares | 24.1M | 19.98M | 26.59M | 30.54M | 33.54M |
| Weighted Avg Shares (Diluted) | 24.1M | 19.98M | 26.59M | 30.54M | 33.54M |
Belite Bio, Inc
NASDAQ:BLTE
Intrinsic Alpha fair value
Locked
Current Price
$156.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.